Accelerate Diagnostics (NASDAQ:AXDX) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX) in a research report issued on Wednesday. The brokerage set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research upgraded Accelerate Diagnostics to a “strong-buy” rating in a report on Wednesday, December 11th.

Accelerate Diagnostics Trading Down 0.8 %

NASDAQ AXDX opened at $1.31 on Wednesday. The stock’s 50-day moving average price is $1.27 and its two-hundred day moving average price is $1.55. The company has a market cap of $32.80 million, a PE ratio of -0.46 and a beta of 0.61. Accelerate Diagnostics has a 1 year low of $0.73 and a 1 year high of $2.09.

Insider Activity at Accelerate Diagnostics

In related news, Director John Patience bought 200,000 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The stock was purchased at an average price of $1.57 per share, with a total value of $314,000.00. Following the completion of the transaction, the director now directly owns 653,224 shares of the company’s stock, valued at $1,025,561.68. This trade represents a 44.13 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 43.60% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Accelerate Diagnostics

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd acquired a new stake in Accelerate Diagnostics, Inc. (NASDAQ:AXDX) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent quarter. 17.14% of the stock is owned by hedge funds and other institutional investors.

About Accelerate Diagnostics

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.